5th Annual Summit on Life Sciences IP Due Diligence - DS

IP due diligence is a key priority for life science companies at many stages of maturity – from early-stage companies seeking venture capital investments, to more mature companies preparing to license or commercialize IP assets or preparing for an initial public offering, to established companies seeking to expand existing markets, enter new markets, divest a business unit or technology, or optimize or reorganize IP assets.

ACI’s 5th Annual Life Sciences IP Due Diligence Summit is designed to provide corporate and IP counsel with winning strategies for assessing, valuing and commercializing IP assets when conducting strategic IP due diligence.

Our esteemed speakers will provide key insights into recent legal developments affecting your analyses of validity, scope, enforceability, ownership, inventorship, and then extrapolate those changes to the penultimate freedom-to-operate opinion and the development of updated IP checklists. You will learn the life sciences IP due diligence considerations unique to M&As, joint ventures, research and collaboration, as well as distressed assets from companies undergoing bankruptcy, insolvency, and restructuring.

In addition, because the lines between the various facets of due diligence are becoming increasingly blurred in today’s fast-paced, innovative, and technology-driven world, ACI is pleased to introduce a special three-part Think Tank on the theme of Bridging the Gap Between Business and IP, featuring sessions on regulatory considerations, financial IP valuation, and a special roundtable wherein venture capitalists and business executives share best practices on how to synergize IP due diligence with business goals.

Our pre-conference workshop primer will teach you the due diligence process from soup to nuts, including reverse due diligence, and our retrospective session will put on your radar the common and uncommon reasons that deals fall through at the eleventh hour, so that you can think proactively and strategize preventatively.

While each deal is unique, with different timelines, resources, priorities and goals, our robust two-day conference guarantees that you will walk with new strategies or insights for your particular transaction. We look forward to welcoming you to Boston.

Supported By

ACI’s 5th Annual Summit on Life Sciences IP Due Diligence will guide you on the latest strategies for assessing, valuing, and commercializing IP assets.

We're back in Boston this November!

Distinguished Faculty

Keynotes

Julia Tierney

Chief of Staff

Food and Drug Administration (FDA) (Washington, DC)

Kendalle Burlin O’Connell President and COO MassBio (Boston, MA)

Speakers

Jeremy Bond

Leader of Digital and Device

Patents, US & Patent Analytics Sanofi (Cambridge, MA)

Gregory Bokar

Executive Vice President, General Counsel and Corporate Secretary Sunovion Pharmaceuticals Inc./ Sumitomo Pharma America Inc (Marlborough, MA)

Chen Chen, Ph.D Partner Cooley LLP (Boston, MA)

Fangli Chen, Ph.D. Partner, Vice-Chair of Life Sciences Patent Group Proskauer Rose LLP (Boston, MA)

Ryan Daniel VP, Associate General Counsel, Corporate and Business Transactions Fresenius Kabi USA (Chicago, IL)

Jonathan Davies Partner

Cooley LLP (Washington, D.C)

Julia-Frost Davies Partner Morgan, Lewis, & Bockius LLP (Mansfield, MA)

David E. De Lorenzi Chair, Intellectual Property Gibbons P.C. (Newark, NJ)

David Dykeman

Partner, Co-Chair of Global Life Sciences & Medical Technology Group Greenberg Traurig LLP (Boston, MA)

Gloria Fuentes

VP & Assistant General Counsel Bristol Myers Squibb (New York, NY)

Susan Glovsky

Principal Hamilton, Brook, Smith & Reynolds, P.C (Concord, MA)

Henry H. Gu

SVP, Head of Intellectual Property Zentalis Pharmaceuticals (New York, NY)

Justin Huddleson Principal Counsel, Global IP Sanofi (Cambridge, MA)

Co-Chairs

Kiera Mathey

Associate Patent Counsel, IP Transactions Johnson & Johnson (Summit, NJ)

Bart Newland General Counsel Atalanta Therapeutics (Boston, MA)

Keisha Hylton-Rodic, Ph.D., Esq Founding Partner

Hylton-Rodic Law PLLC (Washington, D.C)

Thomas L. Irving Partner

Finnegan, Henderson, Farabow, Garrett & Dunner LLP (Vienna, VA)

Colleen Tracy James Partner

White & Case LLP (New York, NY)

Lacy Kolo Managing Director Magnus Partners Inc. (Leesburg, VA)

Jay Lessler Partner Blank Rome LLP (New York, NY)

Michael Levy Senior Counsel, M&A IP Danaher Corporation (Washington, D.C)

Hilary J. Libka

Associate General Counsel & Chief Intellectual Property Counsel Memorial Sloan-Kettering Cancer Center (New York, NY)

Forrester Liddle Vice President, Intellectual Property and Contracts Jounce Therapeutics (Cambridge, MA)

Peter Milner, MD CEO and Founder Renexxion (Tipperary, Ireland)

Donna M. Meuth

Associate General Counsel Intellectual Property Eisai Inc. (Boston, MA)

Jennifer Grant Moitoso SVP, Chief IP Counsel Biogen (Cambridge, MA)

Randall Morin General Counsel Photys (Cambridge, MA)

Ahmed Mousa

Chief Business Officer & General Counsel Pieris Pharmaceuticals (Boston, MA)

Daniel Miao Cheng

President, Founding Partner Cheng & Peng Intellectual Property Law Office (Beijing, China)

Mercedes Meyer Partner

Banner Witcoff (Washington, DC)

Tinh Nguyen

Senior Patent Counsel

Akebia Therapeutics (Boston, MA)

Adam Poulin-Kerstien Vice President, Head of IP Dyno Therapeutics (Cambridge, MA)

Alicia Russo

Partner, Chair of IP Transactional Group Venable Fitzpatrick LLP (New York, NY)

Jennifer A. Sanfilippo General Counsel and Chief Compliance Officer Melinta Therapeutics (Parsippany, NJ)

Len Smith Founding Partner, Principal Counsel Transformative Legal (Scottsdale, AR)

James Southard, JD Compliance Manager CARB-X (Boston, MA)

Michael Stern Of Counsel Covington & Burling LLP (Washington, D.C)

William Vickery Due Diligence Director | Global Business Development Servier (Paris, France)

Marina Volin VP, General Counsel and Corporate Secretary Amring Pharmaceuticals Inc. (Berwyn, PA)

Lindsey A. Wanner Senior Counsel II, IP Alliance and Due Diligence Gilead Sciences, Inc. (San Francisco, CA)

Ha Kung Wong Partner

Venable Fitzpatrick LLP (New York, NY)

Pre-Conference Workshop Monday, November 14,

1:00–4:30 PM

IP DUE DILIGENCE 101: Managing the IP Due Diligence Process from Soup to Nuts

Microphone Jay Lessler, Partner, Blank Rome (New York, NY)

Susan Glovsky, Principal, Hamilton, Brook, Smith & Reynolds, P.C (Boston, MA)

Tinh Nguyen, Sr. Patent Counsel, Akebia Therapeutics, Inc (Boston, MA)

Michael Levy, Senior Counsel, M&A IP, Danaher Corporation (Washington, D.C)

For life sciences companies, intellectual property often represents most of their value. Securing investment, licensing opportunities, and partnerships is dependent upon the strength and valuation of the patent portfolio, making IP due diligence essential to determine value and identify risk.

This interactive think tank will prepare you for the main conference and provide an in-depth overview of the key aspects of a comprehensive IP due diligence investigation. Leading patent practitioners will cover the ins and outs of the challenges that arise during the IP due diligence process, from the perspective of both target and acquirer. Topics to be discussed include:

• Evaluating the breadth, strength, and validity of the patents at issue to calculate the commercial viability of the IP at issue

• Designing the checklists for different levels that will be most efficient in guiding attendees to obtain the information needed

• Quantifying the value of the IP at stake in the deal for both the business and legal teams

• Uncovering and resolving hidden issues with ownership rights, inventorship, and obligations under prior contractual agreements

• Understanding which IP red flags make or break deals, and how to communicate the fixes on problems discovered

• Protecting and preserving confidentiality and privilege during the IP due diligence process

• Gauging the effect of the patents in question on the freedom to operate

• Dealing with biotech patent scrums, Queen patents and PCR to CRISPR

Main Conference Day One

Tuesday, November 15, 2022

7:45 Breakfast and Registration

8:45

Opening Remarks from the Co-Chairs

Microphone Bart Newland, General Counsel, Atalanta Therapeutics (Boston, MA)

Kiera Mathey, Associate Patent Counsel, IP Transactions, Johnson & Johnson (Summit, NJ)

9:00

Keynote

Microphone Kendalle Burlin O’Connell, President and COO, MassBio (Boston, MA)

9:30

One Size Does Not Fit All: Tailoring Life Sciences IP Due Diligence to the Transaction

Microphone Gloria Fuentes, VP & Assistant General Counsel, Bristol Myers Squibb (New York, NY)

Hilary J. Libka, Associate General Counsel & Chief Intellectual Property Counsel, Memorial Sloan-Kettering Cancer Center (New York, NY)

Chen Chen, Ph.D, Partner, Cooley LLP (Boston, MA)

Mergers, acquisitions, and joint ventures are some of the most lucrative transactions in the life sciences space. Licensing and collaborating with other companies or universities can be profitable, assuming that you have properly conducted your IP due diligence and are using those results strategically when entering into the licensing deal or collaboration. The same due diligence checklist cannot be used for these transactions, and the acquirers will have different considerations from the acquirees. This session will teach you the unique diligence considerations for each.

Research and Research Grants, Collaboration and Licenses

• Exhaustive pre-due diligence intelligence that must be gathered before preparing to in-license or acquire a target

• Spotting the red flags in collaboration agreements and CROs

• Updated due diligence checklists for transactions involving government research grants

» Knowing where duty of candor and inequitable conduct falls into the checklist

» Discovering the type of information disclosure statement (IDS) used by the target and assessing the global dossier

» Extrapolating the impact of the Larson, Dayco, McKesson and Therasense cases

• Thoroughly reviewing and negotiating licensing considerations: exclusive or non-exclusive; field of use restrictions; terminal disclaimers; ownership of improvements; royalties; and termination provisions

• Determining inventorship and ownership with multiple inventors and assessing the risk of correlated litigation

• Considering the Bayh Doyle Act and recent march-in petitions

M&As and Joint Ventures

• Due Diligence leadership during the long and complicated merger and acquisitions process

• Analyzing potential trade secrets and avoiding contamination of your team

• Seeking anti-trust opinions, and knowing when and why

• Searching copyright, trademark, and other databases

• Considering the different acquisition, formation and contribution models and identifying the model best suited for each company’s goals

• Reviewing the next steps following the IP due diligence opinion

10:45 Networking Break

11:00

Ownership and Inventorship 2.0: Common and Contemporary IP Due Diligence Landmines for the Life Sciences

Microphone Forrester Liddle, Vice President, Intellectual Property and Contracts, Jounce Therapeutics (Cambridge, MA)

Alicia Russo, Partner, Chair of IP Transactional Group, Venable (New York, NY)

David Dykeman, Partner, Co-Chair of Global Life Sciences & Medical Technology Group, Greenberg Traurig LLP (Boston, MA)

Jeremy Bond, Leader of Digital and Device Patents, US & Patent Analytics, Sanofi (Cambridge, MA)

Inventorship and ownership are fundamental to any deal and can cause chaos when a company gets it wrong. As the number of listed inventors increases, so too do your diligence obligations. As new inventions that incorporate or benefit from artificial intelligence gain popularity, questions remain as to inventorship and ownership over invention conceived by AI. Topics of discussion will include:

• Reviewing legal developments on the question of whether AI or technology can be an inventor (including the DABUS case) and the implications for life sciences companies employing AI technologies

• Developing unique due diligence strategies for life sciences IP assets involving AI, machine learning, proprietary data, software

• Analyzing who owns data, genetic data, and checking for data bias

• Determining inventorship and ownership with multiple inventors and assessing the risk of correlated litigation

» Including a special look at states with community property

• Analyzing the target company’s policies and relationships

» the inventorship determination process, licenses or collaboration with universities, the use of contract research organizations (CROs), and the assignment clauses in employment contracts

12:00

Great

panels, lots of diversity of practice, and lots of seasoned practitioners.

The Freedom to Operate Opinion: Practical Advice and Winning Strategies for Innovation and Negotiation

Microphone Ryan Daniel, VP, Associate General Counsel, Corporate and Business Transactions, Fresenius Kabi USA (Chicago, IL)

Lindsey A. Wanner, Senior Counsel II, IP Alliance and Due Diligence, Gilead Sciences, Inc. (San Francisco, CA)

Jonathan Davies, Partner, Cooley LLP (Washington, DC)

Integrating the Freedom to Operate (FTO) analysis in the product development cycle is of the utmost importance. Life sciences companies should make every effort to ensure that the commercialization of new products or services does not infringe any existing patents owned by third parties. The failure to do so could lead to dire, and expensive consequences. In this session, topics of discussion will include:

• Carefully defining the scope of the patent search strategies

• Understanding where and how patent infringement risks lie and how to manage those risks prior to commercialization, and relative to clinical trial timing

• Strategizing where the problematic claims support both broad and narrow constructions regarding their scope

• Assessing the strength of third-party blocking patents and drafting the necessary litigation opinion

• Triaging the essentials that outside counsel should present to in-house

1:00 Networking Lunch

2:15

Validity, Scope, and Enforceability: Determining the Breadth and Strength of Coverage

Microphone Ha Kung Wong, Partner, Venable (New York, NY)

Jennifer Grant Moitoso, SVP, Chief IP Counsel, Biogen (Cambridge, MA)

Justin Huddleson, Principal Counsel, Global IP, Sanofi (Cambridge, MA)

Henry H. Gu, SVP, Head of Intellectual Property, Zentalis Pharmaceuticals (New York, NY)

The scope, validity and enforceability analyses assess the breadth of protection and strength of coverage of the target company’s IP assets. IP should cover products of commercial interest that drive the deal. Equally, understanding the scope is critical for identifying infringers. In this session, leading in-house and outside counsel will extrapolate the impact of recent court decisions, legislative actions, and cadence on your life sciences IP due diligence practice:

• Reviewing legal developments that may trickle down to affect your due diligence practice

• Discovering and responding to potential inequitable conduct

• Dealing with the narrow scope of important claims

• Knowing when to work with the target company and when to walk away

3:15 Networking Break

#IPDueDiligence twitter: @ACI_Conferences

linkedin: ACI: Pharmaceuticals / Biotech / Medical DeviceLegal, Regulatory, IP and Compliance Professionals

3:30

Navigating the Complexities of Distressed Assets: Advanced Preparations in Times of Uncertainty

Microphone Jennifer A. Sanfilippo, General Counsel and Chief Compliance Officer, Melinta Therapeutics (Parsippany, NJ)

Peter Milner, MD, CEO and Founder, Renexxion (Tipperary, Ireland)

Julia-Frost Davies, Partner, Morgan, Lewis, & Bockius LLP (Mansfield, MA)

In these uncertain times, extra and advanced preparation is needed. IP is a corporate asset and given that no company is immune to an economic slowdown, understanding how IP assets and related IP licenses can be affected in U.S. insolvency and restructuring scenarios, should be on your radar.

• Reviewing general principles of the Bankruptcy Code: Chapter 7 principles (insolvency) and Chapter 11 principles (restructuring) for patents, licenses, trademarks and trade secrets

• Navigating license rights when the licensor goes bankrupt

• Understanding how courts can use the Bankruptcy Code to fundamentally alter or extinguish certain licensed IP rights or affect a party’s ability to enforce its IP rights against the debtor

• Considering litigation strategies for pre-petition claims, post-petition claims, and disaggregation of IP rights

4:30

International Collaboration and Cooperation:

Successfully Expanding Your Life Sciences IP Due Diligence Strategy for Global Deals

Microphone Daniel Miao Cheng, President, Founding Partner, Cheng & Peng Intellectual Property Law Office (Beijing, China)

William Vickery, Due Diligence Director | Global Business Development, Servier (Paris, France)

Colleen Tracy James, Partner, White & Case LLP (New York, NY)

The global economy is becoming more innovation-driven—powered by knowledge, creativity, and technology, each of which is fundamentally supported by IP. Increased globalization therefore requires revised due diligence processes for acquirers and acquirees, and this session will get you refreshed and replenish your due diligence toolkit. Topics of discussion will include:

• Reviewing major legal developments that make the life sciences’ markets more or less attractive in several prominent countries

» E.g., learning the different considerations to obtain market approval in Japan vs. the EMA vs. the FDA

• Learning the new items that need to be added to your international due diligence checklist, such as antitrust and CFUIS risks; annuity fees; manufacturing and supply chain; which databases to search

• Best practices for communicating with lawyers from other countries (e.g., overcoming cultural differences, differences in disclosure requirements, etc.)

• Incorporating lessons from the diligence process to facilitate ultimate integration

• Where to test-start litigation globally

• Transferring data across national borders and export control

5:30 Cocktail Reception

6:30 Day One Adjourns

7:45

8:45

Breakfast and Registration

Opening Remarks from the Co-Chairs

Microphone Bart Newland, General Counsel, Atalanta Therapeutics (Boston, MA)

Kiera Mathey, Associate Patent Counsel, IP Transactions, Johnson & Johnson (Summit, NJ)

9:00

Keynote

Microphone Julia Tierney, Chief of Staff, Food and Drug Administration (FDA) (Washington, DC)

3-Part Think Tank BRIDGING THE GAP BETWEEN BUSINESS AND IP

Main Conference Day Two Wednesday, November 16, 2022 cogs

9:45

PART I

Navigating Complex Pathways and Other Regulatory Considerations in Life Sciences IP Due Diligence

Microphone Marina Volin, VP, General Counsel and Corporate Secretary, Amring Pharmaceuticals Inc. (Berwyn, PA)

Adam Poulin-Kerstien, Vice President, Head of IP, Dyno Therapeutics (Cambridge, MA)

Michael Stern, Of Counsel, Covington & Burling LLP (Washington, D.C)

Understanding regulatory due diligence is mission critical for medical device and drug innovation; whether you can obtain market approval and the ability to meet regulatory deadlines is a key consideration in life sciences IP due diligence.In this session, you will learn:

• How the effect of recent legislative changes and judicial decisions may impact treatment of orphan drugs and medical devices

• The importance of knowing and following the PTE, NDA and Orange Book deadlines

• Understanding data exclusivity

• Considerations around loss of exclusivity and competition when entering the market

• How and when to pick a trademark name and navigating foreign language issues

10:45

Networking Break

11:00 PART II

Translating Due Diligence into Business Value Through IP Valuation

Microphone Fangli Chen, Ph.D, Partner, Vice-Chair of Life Sciences Patent Group, Proskauer Rose LLP (Boston, MA)

Ahmed Mousa, Chief Business Officer & General Counsel, Pieris Pharmaceuticals (Boston, MA)

Len Smith, Founding Partner, Principal Counsel, Transformative Legal (Scottsdale, AR)

Randall Morin, General Counsel, Photys (Cambridge, MA)

The valuation of IP assets is a crucial process which typically drives the deal. And yet, many IP due diligence practitioners in life sciences do not know enough about the process. The more you understand what drives the deal, the better you can tailor your advice to your clients. Continuing with the theme of bridging the gap between business and IP, in this final session of the series, you will learn:

• The IP valuation prerequisites, basic terminology, and the factors that influence IP valuation

• Analyzing a valuation report that will most accurately measure the commercial potential of the target

• Understanding the commonly used methods for IP valuation (e.g., the income method, the market method, and the cost method)

• Distinctions in IP valuation for investment, purchase, joint venture, acquisition, and licensing.

• Reassessing the valuation upon discovering problems with the target company’s patents during due diligence

12:00 PART III

The Investors and Senior Management Speak: Special Roundtable

Intellectual property due diligence is just one of several types of due diligence involved in corporate transactions. IP counsel, whether outside counsel, in-house, or both, present their findings to senior management for the final say. In this special roundtable, investors from venture capital firms and senior management from an in-house biotech and pharma company will share their perspectives on the best ways to bridge the gap between business and IP. Topics of discussion will include:

• Knowing which questions to ask and which conversations to have to fit due diligence within the company’s business strategy

• Incorporating the company’s business strategy and brand into IP due diligence to improve negotiation of the key elements of the proposed transaction

• Working with the company’s bottom line: which IP due diligence red flags are deal-breakers, and which are salvageable from the business perspective

Microphone Samuel Rollins, VP, Legal, Beam Therapeutics (Boston, MA)

James Southard, JD, Compliance Manager, CARB-X (Boston, MA)

Lacy Kolo, Managing Director, Magnus Partners Inc. (Leesburg, VA)

1:00

2:30

Networking Lunch

Retrospective: Lessons Learned from Deals that Fell Through at the Eleventh Hour

Microphone Keisha Hylton-Rodic, Ph.D., Esq, Founding Partner, HyltonRodic Law PLLC (Washington, DC)

David E. De Lorenzi, Chair, Intellectual Property, Gibbons P.C. (Newark, NJ)

Gregory Bokar, Executive Vice President, General Counsel and Corporate Secretary, Sunovion Pharmaceuticals Inc./Sumitomo Pharma America Inc (Marlborough, MA)

In this retrospective, outside counsel in-house counsel will discuss problematic deals that fell through, what went wrong, how they could have avoided them, and how they have adapted their approach for the future. Points of discussion will include:

• Learning the traditional and less traditional deal-breakers

» E.g., over-fraternization between the board of directors, general counsel, target board, and other entities

• Creating new opportunities in product development

• Avoiding pitfalls in the failure to launch

• Identifying the relevant benchmarks to measure success in your checklist

• Mitigating any potential fallout from the failed deal

• Changes to IP due diligence strategy considering lessons learned from failed deals

3:30 Networking Break

3:45

Ethical Dilemmas that Arise in Life Sciences IP Due Diligence: Key Strategies for Identification and Prevention

Microphone Thomas L. Irving, Partner, Finnegan, Henderson, Farabow, Garrett & Dunner LLP (Vienna, VA)

Mercedes Meyer, Partner, Banner Witcoff (Washington, D.C)

Donna M. Meuth, Associate General Counsel, Intellectual Property, Eisai Inc. (Boston, MA)

In this interactive ethics session, learn about common ethical considerations that arise in IP due diligence and how to protect yourself from those risks. Topics of discussion include:

• How to work with outside counsel to avoid contamination

• Duty to report misconduct

• Learning the capabilities and conflicts with Board of Directors

• Unpacking data bias and data integrity

• Inequitable conduct and duties of candor to courts, tribunals, and the USPTO

» Duties to disclose, report misconduct, etc

4:45 Conference Concludes

due

Bed VENUE INFORMATION

Hotel: The Westin Copley Place

Address: 10 Huntington Avenue, Boston, MA, 02116

Reservations: (617) 262-9600

American Conference Institute is pleased to offer our delegates a limited number of hotel rooms at a negotiated rate. To take advantage of these rates, please contact the hotel directly and quote “Life Sciences IP Due Diligence

hands-helping BECOME A SPONSOR

With conferences in the United States, Europe, Asia Pacific, and Latin America, the C5 Group of Companies: American Conference Institute, The Canadian Institute, and C5 Group, provides a diverse portfolio of conferences, events and roundtables devoted to providing business intelligence to senior decision makers responding to challenges around the world.

Don’t miss the opportunity to maximize participation or showcase your organization’s services and talent. For more information please contact us at: SponsorInfo@AmericanConference.com

Hearing from professionals involved in

diligence on a daily basis was very informative.

Planning Ahead for Live Conferences: C5’s All Secure Safety Plan

As American Conference Institute and our partners plan for in-person events, we are committed to building and enhancing the planning and preparation with a view to offering our guests a safe place for live conference delivery. In addition, to ensure your safety, our event staff is fully vaccinated.

All our events will adhere to official government and local authority guidance in addition to venue or location-specific regulations, and will follow the commitments below.

Attendance Screening

All attendees will need to assert that at the time that they first attend the conference and for the 10 days prior:

y Have not experienced any COVID-19 symptoms now or within the last 10 days.

y Have not had close contact with any person with or suspected of having COVID-19 within the last 10 days.

y Have not had a positive COVID-19 test within the last 10 days.

y Have not been advised by any health authority, government agency or regulatory body, within the last 10 days, to self-isolate due to possible exposure to COVID-19.

Link to COVID-19 symptoms: https://www.cdc.gov/coronavirus/2019-ncov/symptoms-testing/ symptoms.html

We are closely monitoring industry best practices and will be evaluating further additional measures pertaining to vaccinations and on-site screening based on the advice of health authorities.

Enhanced Communication

y Advance communication to all attendees on what to expect and prepare for at the conference: from registration to conference materials to room layout to food and beverage options and more.

y Education and training for the team to ensure we provide a safe and secure conference experience.

y Distribution of local health-resource information in advance of the event.

y Ongoing communication and advance planning with the venue regarding enhanced cleaning and sanitizing measures, response strategies and other onsite protocols.

Increased Cleaning and Sanitation

y Placement of hygiene stations throughout the conference including the registration area, meeting spaces and high frequency areas.

y Availability of personal hygiene and safety products including facial coverings where available.

Safety and Physical Distancing

y Physical distancing protocols such as limiting attendance, directional signage and markers throughout the conference.

y A conference room layout with planned seating for appropriate physical distancing.

y We continue to work closely with our venue partners to ensure the safety of our attendees. Please check back frequently as we monitor and evolve our plan in the weeks ahead.

Reduced Touchpoints

y Reduction of the physical distribution of onsite materials.

y Food and beverage options that ensure minimal handling and exposure.